1. "Biomed Central Ltd"
  2. "2020"
Formats
  1. Journal Article (47)
  2. Meeting Abstract (39)
  3. Guidelines (6)
  4. Review (3)
  5. Editorial (2)
  6. Miscellaneous (1)
  7. Research Letter (1)
Groups
  1. Department of Medicine (70)
  2. Solid Tumor Oncology Division (60)
  3. GSK Faculty (23)
  4. Sloan Kettering Institute Postdocs (22)
  5. Hematologic Malignancies, Division of (21)
  6. Melanoma and Immunotherapeutics Service (21)

More Groups

People
  1. Jedd Wolchok (8)
  2. Michael Postow (8)
  3. Taha Merghoub (8)
  4. Dmitriy Zamarin (7)
  5. Sandra D'Angelo (6)
  6. Roberta Zappasodi (5)

More People

Years
  1. 2020 (99)
Publications
  1. Journal for ImmunoTherapy of Cancer (58)
  2. Breast Cancer Research (6)
  3. BMC Cancer (4)
  4. Journal of Translational Medicine (4)
  5. BMC Medicine (3)
  6. Journal of Hematology & Oncology (3)

More Publications

Publishers
  1. Biomed Central Ltd (99)

Results (99)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characterizing double positive T cells in the tumor microenvironment: A tale of promiscuous cell fates
    Meeting Abstract

    Schad, S.; Chow, A.; Pan, H.; Mangarin, L.; Zappasodi, R.; Gigoux, M.; Redmond, D.; Hirschhorn-Cymerman, D.; Budhu, S.; Zhong, H.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Tired and hungry: A potential role for CD47 in T cell exhaustion
    Meeting Abstract

    Mangarin, L.; Liu, C.; Zappasodi, R.; Holland, P.; Wolchok, J.; Merghoub, T.; Weng, C. H.; Weng, C. H.; Schroder, D.
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Tim-4(+) resident macrophages impair anti-tumor immunity in the serous body cavities by sequestering viable and cytotoxic CD8(+) T cells expressing high levels of phosphatidylserine
    Meeting Abstract

    Chow, A.; Schad, S.; Green, M.; Hellmann, M.; Ceglia, N.; Allaj, V.; Zago, G.; Shah, N.; Sharma, S.; Mattar, M.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Concordance between healthcare providers and expert consensus recommendations in the management, monitoring, and mitigation of adverse events associated with CAR T-cell therapy: An updated analysis
    Meeting Abstract

    Frigault, M.; Cartwright, M.; Marcello, K.; Quill, T.; DeAngelo, D.; Galinsky, I.; Paul, S.; Park, J.
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination
    Meeting Abstract

    Gigoux, M.; Zappasodi, R.; Park, J.; Pourpe, S.; Ghosh, A.; Bozkus, C. C.; Mangarin, L.; Redmond, D.; Verma, S.; Schad, S.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Radiotherapy and CTLA-4 blockade expand antitumor T cells differentiation states and cooperate with CD40 agonist to induce tumor rejection
    Meeting Abstract

    Rudqvist, N.; Lhuillier, C.; Charpentier, M.; Wennerberg, E.; Spada, S.; Sheridan, C.; Zhou, X. K.; Zhang, T.; Sims, J.; Alonso, A.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Updated clinical data from the melanoma expansion cohort of an ongoing ph1/1b study of eganelisib (formerly IPI-549) in combination with nivolumab
    Meeting Abstract

    Postow, M.; Sullivan, R.; Cohen, E.; Gutierrez, M.; Hong, D.; Steuer, C.; McCarter, J.; Zizlsperger, N.; Kutok, J.; O'Connell, B.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Safety and preliminary efficacy of intratumoral cavrotolimod (AST-008), a spherical nucleic acid TLR9 agonist, in combination with pembrolizumab in patients with advanced solid tumors
    Meeting Abstract

    O'Day, S.; Perez, C.; Wise-Draper, T.; Hanna, G.; Bhatia, S.; Kelly, C.; Medina, T.; Laux, D.; Daud, A.; Chandra, S.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma
    Meeting Abstract

    Dummer, R.; Long, G. V.; Pavlick, A.; Postow, M.; Ribas, A.; Robert, C.; Scolyer, R. A.; Taube, J.; Tetzlaff, M.; Liao, J.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Interim analysis of phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (MBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIS)
    Meeting Abstract

    Lewis, K.; Peris, K.; Sekulic, A.; Stratigos, A.; Dunn, L.; Eroglu, Z.; Chang, A. L.; Migden, M.; Li, S.; Mohan, K.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save